Latest News
Get real-time updates on the latest news and developments in the pharmaceutical world. Stay informed about new drug launches, research findings, regulatory changes, and industry updates. Explore a wide range of topics and stay connected with the rapidly evolving world of pharma.
GSK’s Jemperli Shows Promise in Endometrial Cancer Trial – FDA Label Expansion on the Horizon
GSK has achieved a significant milestone with its PD-1 inhibitor, Jemperli, in the treatment of endometrial cancer, potentially opening the ...
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead
Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...
Klick Health Welcomes Ellen Cappellino, Former AstraZeneca and Vertex Executive, as Value, Access, and Reimbursement Director
Klick Health, a prominent healthcare marketing agency, has recently appointed Ellen Cappellino, a distinguished figure in the pharmaceutical industry, to ...
ElevateBio slashes 13% of workforce despite huge fundraising
Despite having a substantial $401 million in funding, ElevateBio is streamlining its operations, resulting in job cuts that will impact ...
UCBās Swiss plant gets Form 483 from FDA over quality and records
UCB Farchim, a subsidiary of Belgian pharmaceutical company UCB, is facing regulatory scrutiny from the FDA. The FDA recently issued ...
Bristol Myersā new CEO aims to boost weak new drug launches
Bristol Myers Squibb (BMS) is addressing concerns about its underperforming new products, expressing confidence in their future success. The company’s ...
Eisai, Biogenās Leqembi reduces amyloid in Alzheimerās, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Takeda writes off $770M after failures of Alofisel and Exkivity
Takeda, the Japanese pharmaceutical company, is grappling with significant impairment charges totaling 115.8 billion Japanese yen ($770 million) in its ...
EuroAPI chief Karl Rotthier resigns amid strategic review
In a swift and significant personnel decision, EuroAPI’s board of directors has announced the departure of CEO Karl Rotthier, effective ...
RLS to offer CDMO services for radiopharma at 8 US locations
The biopharmaceutical landscape is witnessing a seismic shift towards radiopharmaceuticals, with major players like Eli Lilly making substantial investments, exemplified ...
Accenture Song acquires ConcentricLife for $245M to boost ad capabilities
Accenture, known for its relentless pursuit of acquisitions, has returned to the deal table once again. The global services company, ...
Merck boosts revenue outlook on COVID-19 pill Lagevrio demand
In a surprising turn of events, Merck’s COVID-19 antiviral pill, Lagevrio, has defied expectations by generating an astounding $640 million ...
3M CEO updates on healthcare spinoff amid revenue decline
In a recent company update, 3M has provided insights into the status of its long-anticipated healthcare business spinout, indicating that ...
Alnylam, Biogen show gene-silencing data for Alzheimerās therapies
This week, Alnylam and Biogen took a significant step toward redefining the landscape of Alzheimer’s disease treatment by revealing promising ...
Pfizer, BioNTech ready flu-COVID combo vaccine for phase 3 trial
In an exciting race reminiscent of their previous encounters, Pfizer and BioNTech have once again taken on their recurring competitor, ...
BioSenic seeks to survive cash crunch and enter phase 3 for GvHD drug
BioSenic, the Belgian biotech born from the merger of Bone Therapeutics and Medsenic last year, is devising a survival plan ...
Roche, Biogen end patent dispute over Actemra biosimilar
Roche has swiftly resolved a patent infringement lawsuit it initiated against Biogen in July. The legal dispute centered around Biogen’s ...
GSKās RSV vaccine poised for label expansion after trial success
Five months after GSK made history by securing FDA approval for its respiratory syncytial virus (RSV) vaccine, Arexvy, the company ...
Araclonās Alzheimerās vaccine shows promise in phase 2 trial
Araclon Biotech, a subsidiary of Grifols, has unveiled promising early evidence regarding the effectiveness of its Alzheimer’s disease vaccine. In ...
AstraZenecaās nasal flu vaccine nears FDA approval
AstraZeneca’s FluMist, a nasal spray flu vaccine with a two-decade history, is poised to potentially become available for self-administration as ...
RSV outbreak causes shortage of Sanofi, AZās Beyfortus
Shortly after Sanofi and AstraZeneca secured a significant FDA approval for their respiratory syncytial virus (RSV) antibody, Beyfortus, the highly ...
Amgen to cut 350 jobs after acquiring Horizon for $28 billion
Recently, in the aftermath of Amgen’s substantial $27.8 billion acquisition of Horizon, unveiled in December and finalized this month, these ...
Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership
Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...
Idorsia slashes 300 jobs in R&D amid cost-cutting efforts
The company has announced that it will be reducing its workforce by 300 individuals, with a focus on R&D and ...
Boehringer, Teva, others hit with EU fines for drug-ingredient cartel
Five pharmaceutical companies, including the prominent global firm Boehringer Ingelheim, find themselves in the midst of a regulatory storm, facing ...
Aiolos Bio debuts with $250M and ex-Gyroscope CEO to tackle severe asthma
A striking trend throughout 2023 has been the gravitational pull of significant funding toward promising biotech endeavors. This theme is ...
AxoSim acquires Vyantās organoid tech for brain disorder research
AxoSim, a New Orleans-based drug discovery biotech, has successfully completed the acquisition of the neuroscience research assets from Vyant Bio’s ...
OrbiMed raises $4.3B for 3 funds to back biotech startups
OrbiMed, a major global financier of biopharmaceutical companies, has successfully amassed $4.3 billion, earmarked for investment in emerging healthcare and ...
BrainStorm cuts 30% staff, eyes ALS cell therapy approval
BrainStorm Cell Therapeutics has chosen an unconventional route in response to its recent setback in securing approval. While the decision ...
